Traumatic Brain Injury and Chronic Traumatic Encephalopathy
Traumatic brain injury, or TBI, is a broad term for brain dysfunction caused by an external force such as a fall, car crash, assault, blast exposure, or sports-related impact. It ranges from mild concussion to severe injury with bleeding, swelling, or prolonged loss of consciousness. Some people recover well, especially after a single mild injury, but others are left with persistent problems involving memory, attention, mood, sleep, balance, or headaches.
CTE is related to TBI, but it is not the same thing. It is a specific progressive neurodegenerative disease associated with long-term exposure to repetitive head impacts, especially in contact sports and some military settings. Current evidence does not support the idea that a single concussion, or a small number of occasional head injuries, is enough by itself to establish CTE risk in most people. Not everyone with TBI develops chronic neurodegeneration, and not every long-term symptom after head injury means a person has CTE. But there is now strong evidence that head trauma can, in some people, trigger biological changes that continue well after the initial injury.
Pathology
In TBI, the first injury is mechanical. Brain tissue is stretched, compressed, or sheared by the force of impact. That can cause bruising, bleeding, disruption of axons, and changes in blood flow. But the damage does not stop there. After the initial trauma, the brain can enter a second phase involving inflammation, oxidative stress, excitotoxicity, blood-brain barrier disruption, and metabolic dysfunction. This delayed injury helps explain why symptoms can evolve over hours, days, or longer.
One of the most important pathological features of TBI is diffuse axonal injury, where long nerve fibers are damaged by stretching and shear forces. Axons are especially vulnerable because they are structurally long and depend on intact transport systems to move materials up and down the cell. When that system breaks down, communication between brain regions becomes less reliable, and some axons degenerate over time rather than failing immediately.
CTE has a different pathological signature. It is defined by abnormal deposits of hyperphosphorylated tau in a characteristic pattern, especially around small blood vessels and at the depths of cortical sulci, the folds of the brain. Recent work also suggests that repetitive head impacts can produce early neuron loss and inflammation before the full classic CTE tau pattern is established.
Biological Pathways
One major pathway that is engaged after TBI is neuroinflammation. Immune cells in the brain become activated after injury, and while some of this response is part of repair, prolonged activation can injure surrounding tissue and contribute to chronic symptoms. This has become a major area of research because persistent inflammation may help link an acute injury to later neurodegeneration.
A second major pathway is axon degeneration. Mechanical injury can push axons into a self-destruction program. This is where SARM1 becomes relevant. SARM1 is a central executioner of programmed axon degeneration, and TBI models have increasingly implicated axonal self-destruction pathways in chronic post-traumatic damage, indicating that SARM1 inhibitors may be an appropriate therapy for these patients.
A third pathway is tau pathology and network degeneration, especially in CTE. Repetitive head impacts appear to create tissue strain patterns that help explain where tau pathology begins. Over time, this may contribute to progressive loss of neurons and disruption of brain networks involved in memory, mood, executive function, and behavior.
Causes
The causes of TBI are direct physical injuries, including falls, motor vehicle crashes, sports collisions, and blast exposure. Risk is shaped by both the type of exposure and the context. Older adults are at higher risk from falls, younger adults from vehicle crashes and sports, and certain occupations or environments increase exposure to repeated impacts.
The strongest known risk factor for CTE is repetitive head impacts over time, not just diagnosed concussions alone. This includes exposure in contact sports such as football, boxing, hockey, and rugby, and may also include military and other repeated-impact settings. Dose matters: studies continue to support a relationship between greater cumulative exposure and higher CTE risk.
Genetics may influence how individuals respond to brain injury, but at present the clearest and most established driver of CTE risk is exposure history. That makes prevention especially important, because unlike Huntington’s disease, this is an area where changing exposure can plausibly change disease burden.
Progression
TBI can follow very different courses depending on severity. Some people recover substantially within days to weeks, especially after mild injury, while others have lasting symptoms that persist for months or years. Problems with attention, headaches, mood, sleep, and sensory sensitivity can remain even when structural scans look relatively normal.
When chronic post-traumatic neurodegeneration develops, the timeline is much longer. Symptoms may emerge gradually and can include cognitive decline, emotional instability, depression, impulsivity, or behavioral change. In CTE, these changes are thought to reflect progressive tau pathology and network-level degeneration.
One challenge is that clinical symptoms alone do not prove CTE. At present, CTE is still definitively diagnosed after death through neuropathology, and there is active debate about how best to identify it during life. That uncertainty is important to communicate clearly so the page remains accurate and does not overstate what medicine can currently confirm in living patients.
Treatment Landscape
Treatment for TBI depends on severity and timing. Acute care may involve monitoring, imaging, management of bleeding or swelling, surgery in severe cases, and prevention of secondary brain injury. For milder injuries, treatment usually focuses on symptom-guided recovery, graded return to activity, and management of headaches, dizziness, sleep problems, mood symptoms, and cognitive difficulties.
For chronic symptoms after TBI, treatment is usually supportive rather than disease-modifying. Rehabilitation can include physical therapy, occupational therapy, speech therapy, cognitive rehabilitation, psychotherapy, vestibular therapy, and careful return-to-work or return-to-play planning. There is still no established therapy that reliably halts long-term post-traumatic neurodegeneration once it is underway.
For CTE specifically, there is no approved disease-modifying treatment. The most important “therapy” at the population level is prevention: reducing unnecessary repetitive head impacts, improving sports and occupational safety, and recognizing injury early. On the research side, there is growing interest in targeting inflammation, tau pathology, biomarkers, and axon degeneration pathways such as SARM1, but these remain investigational.
Research Directions
A major research priority is developing better biomarkers for chronic effects of TBI and for possible CTE in living people. Blood, imaging, and cerebrospinal fluid biomarkers are all being studied because current diagnosis relies too heavily on symptoms and exposure history. Better biomarkers would improve prognosis, research studies, and eventually treatment trials.
Another important direction is separating the biology of single-event TBI from the biology of repetitive head impacts. These overlap, but they are not identical. Recent studies suggest repetitive head impacts can cause early neuron loss and inflammation before classic CTE pathology becomes extensive, which may help explain why symptoms and pathology do not always line up neatly.
There is also growing interest in therapies that protect axons and preserve network integrity after injury. That includes work on SARM1 and related degeneration pathways, as well as efforts to understand tau spread, chronic inflammation, and the long-term remodeling of injured circuits. The broader shift is toward seeing head trauma not only as an acute event, but in some cases as the start of a chronic neurodegenerative process.